Cercar
01/07/2022
Industrial By-Products As a Novel Circular Source of Biocompatible Extracellular Vesicles
Lorca, C, Laparra, M, Cespedes, MV, Casani, L, Florit, S, Jove, M, Mota-Martorell, N, Vilella, E, Gallart-Palau, X, Serra, A. Industrial By-Products As a Novel Circular Source of Biocompatible Extracellular Vesicles. ADVANCED FUNCTIONAL MATERIALS. 2022; 32(29)DOI:10.1002/adfm.202202700. PMID:. IF:19.000(Q1/1D).
01/07/2022
Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease
Medina-Gutierrez, E, Cespedes, MV, Gallardo, A, Rioja-Blanco, E, Pavon, MA, Asensio-Puig, L, Farre, L, Alba-Castellon, L, Unzueta, U, Villaverde, A, Vazquez, E, Casanova, I, Mangues, R. Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease. Biomedicines. 2022; 10(7)DOI:10.3390/biomedicines10071680. PMID:35884987. IF:4.700(Q1/3D).
01/04/2022
All-in-one biofabrication and loading of recombinant vaults in human cells
Martin, F, Carreno, A, Mendoza, R, Caruana, P, Rodriguez, F, Bravo, M, Benito, A, Ferrer-Miralles, N, Cespedes, MV, Corchero, JL. All-in-one biofabrication and loading of recombinant vaults in human cells. Biofabrication. 2022; 14(2)DOI:10.1088/1758-5090/ac584d. PMID:35203066. IF:9.000(Q1/2D).
01/04/2022
Neural plasticity of the uterus: New targets for endometrial cancer?
Espanol, P, Luna, R, Soler, C, Caruana, P, Altes-Arranz, A, Rodriguez, F, Porta, O, Sanchez, O, Llurba, E, Rovira, R, Cespedes, MV. Neural plasticity of the uterus: New targets for endometrial cancer?. Womens Health. 2022; 18DOI:10.1177/17455057221095537. PMID:35465787. IF:(Q/D).
01/03/2022
Laparoscopic approach for symptomatic pelvic and para-aortic lymphoceles
Aznar, AL, Lloret, PE, Moreno, CS, Luna-Guibourg, R, Negre, RR. Laparoscopic approach for symptomatic pelvic and para-aortic lymphoceles. Journal Of The Turkish-German Gynecological Association. 2022; 23(1)DOI:10.4274/jtgga.galenos.2021.2021.0028. PMID:34109774. IF:(Q/D).
01/01/2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
Francis K.E., Kim S.I., Friedlander M., Gebski V., Ray-Coquard I., Clamp A., Penson R.T., Oza A., Perri T., Huzarski T., Martin-Lorente C., Cecere S.C., Colombo N., Ataseven B., Fujiwara K., Sonke G., Vergote I., Pujade-Lauraine E., Kim J.-W., Lee C.K.. The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. ANNALS OF ONCOLOGY. 2022; 33(6)DOI:10.1016/j.annonc.2022.02.222. PMID:35219776. IF:50.500(Q1/1D).